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Abstract
Objective—To assess patient satisfaction with vertigo control using intratympanic (IT)
dexamethasone (12 mg/mL) for medically refractory unilateral Ménière’s disease.
Study Design—Retrospective study.
Setting—Tertiary referral neurotology clinic.
Patients—One hundred twenty-nine subjects diagnosed with unilateral Ménière’s disease still
having vertigo despite medical therapy.
Intervention—IT dexamethasone injections as needed to control vertigo attacks.
Main Outcome Measure—A Kaplan-Meier time-to-event method was used to determine the rate
of “survival,” meaning sufficient satisfaction with vertigo control that the subject did not wish to
have subsequent ablative treatment. “Failure” was defined as poor control and the choice to proceed
to ablative treatment.
Results—Acceptable vertigo control (“survival”) was achieved in 117 (91%) of 129 subjects.
Vertigo control required only one dexamethasone injection in 48 (37%), 2 injections in 26 (20%), 3
injections in 18 (14%), and 4 injections in 10 (8%). More than 4 injections were needed in 15 subjects
(21%). Of 12 failures (9%), 9 occurred within 6 months of the first IT dexamethasone injection.
Follow-up data for 2 years were available for 96 subjects. Of these, 87 (91%) had vertigo control
with IT dexamethasone, of whom 61 (70)% required no further injections after 2 years, 23 (26%)
continued to receive IT dexamethasone injections, and 3 (3%) chose IT gentamicin treatment.
Conclusion—IT dexamethasone injection therapy on an as-needed outpatient basis can provide
vertigo control that is satisfactory in patients with Ménière’s disease. The Kaplan-Meier method
addresses the need for an outcome measure suited to repeated treatments and variable lengths of
follow-up. However, due to the retrospective nature of this study, the presence of bias caused by loss
of subjects from follow-up cannot be ruled out.
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Intratympanic (IT) therapies are growing in popularity in the management of vertigo in
Ménière’s disease. The success of IT gentamicin has been examined in a number of series and
summarized in several meta-analyses (1–3). Although vertigo control is achieved in more than
85% of the subjects in these series, hearing loss and posttreatment disequilibrium remain
significant concerns. The success of “titration protocols” for IT gentamicin has inevitably led
to the attempt to use non-ablative IT steroids to control vertigo attacks in Ménière’s disease in
a similar way. A PubMed search found 29 articles related to IT steroid treatment for Ménière’s
disease over the last decade.
IT steroids may have an anti-inflammatory effect on the labyrinth as suggested by the beneficial
response in inner ear disorders with likely immune causes (4). In addition, recent in vitro
physiology studies suggest that steroid perfusion of labyrinthine tissues can affect sodium and
fluid transport (5). Trune et al. (6) have identified a mouse with progressive stria vascularis
dysfunction and hearing loss in which steroids with mineralocorticoid effects ameliorate the
inner ear dysfunction. Therefore, it is also possible that the effects of IT steroids in Ménière’s
disease include an ion or water transport mechanism.
One of the first reports regarding the effects of IT steroids for Ménière’s disease showed 80%
improvement in vertigo and a 74% reduction in tinnitus in 61 patients (7). The use of IT and
intravenous corticosteroids showed short-term control of vertigo in 96.4% and an improvement
in hearing loss in 67.9% of 28 patients in Shea’s stages I to III of Ménière’s disease (8). These
and other preliminary results led Silverstein et al. (9) to conduct a prospective, randomized,
double-blind study to compare IT dexamethasone with sodium hyaluronate versus saline with
sodium hyaluronate. IT dexamethasone did not show benefit over placebo for improving
vertigo, hearing loss, or tinnitus in this small study of subjects with late-stage Ménière’s disease
(Shea’s stage IV). However, other authors have reported good vertigo control rates in the short
term after IT steroid treatment. Sennaroglu et al. (10) found that 72% of their subjects had
satisfactory control of vertigo, 16% had improvement of hearing, and only 8% had worsening
of hearing after IT dexamethasone treatment. In a retrospective study, Barrs (11) reported
control of vertigo with one or more courses of IT injections of dexamethasone in 47% of
patients with intractable Ménière’s disease. A recent prospective, placebo-controlled study
with 2 years’ follow-up demonstrated complete control of vertigo in 82% of those with IT
steroid treatment versus 57% with placebo treatment (12).
Despite these mixed preliminary results, IT steroid therapy appears to be increasing in clinical
practice. This is no doubt influenced by the convenience and ease of repeating these office-
based treatments. Moreover, minimal side effects have been reported related to the IT steroid
therapy (mainly tympanic membrane perforation and inflammatory middle ear changes). The
current study was conducted to determine if one or more IT steroid injections could provide
sufficient relief from vertigo or disequilibrium in Ménière’s disease that ablative treatments
were subsequently avoided. For that purpose, we reviewed records from the previous 8 years
in an academic neurotology practice for subjects who were patients with unilateral Ménière’s
disease that was unresponsive to medical therapy. The subjects were offered ablative therapy
with IT gentamicin, but they were given the option of IT dexamethasone as a nonablative
treatment first. We sought 3 important outcome measures: 1) the number and dates of IT
dexamethasone injections, 2) the number of subjects who abandoned IT dexamethasone in
favor of ablative treatments and when they did so, and 3) the number who continued with IT
dexamethasone injections after 2 years from the first injection.
MATERIALS AND METHODS
This is a retrospective study from November 1997 to May 2006 including patients who were
seen in clinical consultation at the Department of Otolaryngology-Head and Neck Surgery at
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the Johns Hopkins University School of Medicine (Baltimore, MD, USA) and were diagnosed
with definite unilateral Ménière’s disease by the 1995 criteria of the American Academy of
Otolaryngology—Head and Neck Surgery (AAO-HNS). According to these criteria, definite
unilateral Ménière’s disease must meet the following criteria: 1) 2 or more definitive
spontaneous episodes of vertigo of 20 minutes or longer, 2) audiometrically documented
hearing loss on at least 1 occasion, 3) tinnitus or aural fullness in the treated ear, and 4) other
causes excluded (13). None of these subjects responded adequately to dietary or diuretic
treatments, although sodium restriction and diuretic therapy were continued if there was a
history of some beneficial response. The attending physician explained to the patient the pros
and cons of different therapeutic options: IT injection of steroids, IT injection of gentamicin,
endolymphatic sac surgery, vestibular neurectomy, and labyrinthectomy. Patients were offered
IT dexamethasone treatment as an option that might provide temporary relief of vertigo without
destroying vestibular function. Of 132 patients thus counseled, 3 opted for IT gentamicin
immediately, and 129 opted to try IT dexamethasone before proceeding to IT gentamicin. The
latter 129 are the subjects of this study. This study was a review of existing clinical data with
patient identifiers removed. It qualified for exemption from an institutional review board
protocol based on US Department of Health and Human Services criteria 45 CFR 46.101(b4).
The Johns Hopkins Medicine Institutional Review Board made the determination that the study
qualified for this exemption.
The IT steroid injection procedure was performed in the outpatient clinic under a binocular
microscope after informed consent was obtained from the patient. With the patient supine and
the head turned to the opposite side, a drop of phenol was used to induce local anesthesia on
the anterior aspect of the tympanic membrane. The dexamethasone (12 mg/mL) solution was
loaded into a 1-mL tuberculin-type syringe with a long 25-gauge needle attached on it. One
needle hole was made in the anesthetized area for air to escape during the middle ear injection.
A second hole was made for the injection, and the drug solution was infused into the middle
ear space in a quantity (usually 0.4–1.0 mL) sufficient to fill the space or at least cover the
round-window niche. After the injection, the head was placed slightly lower than the body,
and the subject was instructed to lie in the supine position with the head turned 45 degrees
toward the contralateral side, keeping the treated ear up for 30 minutes.
In the following clinical appointments (at 1- to 4-month intervals), vertigo control was assessed
by the subject’s report of the frequency and severity of any vertigo attacks that occurred since
the last treatment. If there were no vertigo attacks reported, then no further therapy was
recommended at that time. If there were any vertigo attacks but the patient was satisfied with
a reduction in the frequency or severity compared with what they had experienced before the
IT dexamethasone injection, then the subject was offered another IT dexamethasone treatment.
However, if the subject felt that the effect of the last IT dexamethasone injection was negligible
or unsatisfactory, then IT gentamicin injection or ablative surgery was recommended.
Measured data were the number and dates of dexamethasone injections that the subjects
received during the period between their first injection and an administrative censor date when
the analysis was initiated (May 9, 2006). For those who failed therapy before the censor date,
we determined the same data as well as when the failure occurred. Records were also reviewed
for evidence of persistent tympanic membrane perforations after injections.
In keeping with the AAO-HNS criteria calling for 2 years’ follow-up for treatment studies in
Ménière’s disease (13), we also determined how many subjects remained on IT dexamethasone
treatment after 2 years from their first injection and how many had chosen one of the other
therapies mentioned. We classified subjects by AAO-HNS stage of Ménière’s disease before
IT dexamethasone treatment, and we assessed in each class the number of injections that the
subjects had received.
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Statistical Analysis
A Kaplan-Meier time-to-event method was used to calculate the percentage of the subjects
who had adequate control of their vertigo over time after initial IT dexamethasone injection
(“survival”) (14). Data for all subjects who did not fail treatment were censored
administratively (i.e., censored due to constraints of when analysis was performed rather than
being lost to follow-up) (15). Kaplan-Meier calculations with 95% confidence intervals
estimated with Greenwood’s formula were performed using Stata 8.2 software (Stata Corp.,
College Station, TX, USA).
RESULTS
The Kaplan-Meier survival curve in Figure 1 demonstrates that 91% (117 of 129) subjects were
sufficiently satisfied with the course of their IT dexamethasone treatments that they did not
choose to go on to a different therapy during the study period. All 12 of the subjects who
selected another therapy selected IT gentamicin treatment. Previous to gentamicin, 5 of these
12 subjects received 1 IT dexamethasone injection, 3 subjects received 2 injections, 3 other
subjects received 4, and one subject received 8. Nine of these 12 failed IT dexamethasone
therapy within the 6 months of the first dexamethasone injection. Eight of these “early” failures
had received 1 or 2 IT dexamethasone injections. One subject failed in the third year after
receiving 4 IT dexamethasone injections. Two subjects failed in the fourth year following their
first IT dexamethasone injections after they received a total of 4 and 8 dexamethasone
injections, respectively.
Vertigo control required only 1 dexamethasone injection in 48 survivors (37%), 2 injections
in 26 (20%), 3 injections in 18 (14%), and 4 injections in 10 (8%). More than 4 injections were
needed in 15 survivors (21%). Table 1 summarizes the cumulative number of dexamethasone
injections given to survivors by each year of follow-up. Most subjects received 1 to 3 IT
dexamethasone injections.
Of the total 129 subjects, 96 had at least 2 years of follow-up. Nine of these subjects (9%)
chose to go on to ablative therapy with IT gentamicin treatment because of unsatisfactory
control of their vertigo. They were considered to be IT dexamethasone treatment “failures.”
The remaining 87 survivors (91%) with at least 2 years of follow-up found satisfactory vertigo
relief with variable numbers of IT dexamethasone injections (Table 1, second column). Of
these, 37 subjects (42%) required no further steroid injections than the first one, 21 (24%)
needed 2 injections, 11 (13%) required 3 injections, 11 (13%) required 4 injections, 3 (3%)
required 5 injection, 3 (3%) required 6 injections, and 1 (1%) required 7 injections as of the 2-
year follow-up point. For 87 subjects with follow-up beyond 2 years, 61 (70%) did not require
any further treatment, 23 (26%) received more IT dexamethasone injections, and 3 (3%) chose
IT gentamicin treatment. Table 2 gives the cumulative number of injections received by
subjects with each stage of Ménière’s disease.
DISCUSSION
IT therapy for Ménière’s disease has evolved since the introduction of “titration protocols” for
IT gentamicin (16). The success of such intermittent, “as-needed” injections of gentamicin
inevitably has led to the similar use of IT steroids. In such treatment schemes, the need for a
second injection would constitute “failure” under the 1995 AAO-HNS criteria. Yet patients
commonly choose to continue with repeated injection therapies instead of proceeding to
surgically ablative ones. In the case of IT steroid injection, the elements underlying the choice
to continue with repeated injections may be numerous, and some are difficult to measure. These
elements may include positive effects of the steroid injection, including actual reduction in the
frequency or severity of vertigo attacks, reduced aural pressure sensation, or even placebo
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effects. The decision may also be affected by the subject’s unease with the risks of other
therapies, for example, IT gentamicin, which carries a greater risk of hearing loss and
imbalance. Other elements affecting the choice for repeated IT steroid injections may include
the perception of ease of treatment on the part of the patient or bias on the part of the
otolaryngologist. The ability to receive immediate intervention soon after the recurrence of
vertigo may give the patient reassurance and a perception of control over their disease that
ultimately relieves the psychological stress that accompanies and may exacerbate this
unpredictable disorder. Whatever the physiological and/or psychological effects of IT steroid
treatment may be in Ménière’s disease, it seems unlikely that patients would persist with this
treatment if they did not consider it to have some beneficial effect on their symptoms.
Despite these ambiguous motivating factors, each choice to receive an IT steroid treatment
represents a discrete and unambiguous decision point that can be used for longitudinal,
quantitative analysis. The Kaplan-Meier method is suited to the type of analysis in this study,
in which subjects had variable durations of follow-up ranging from 6 months to 8 years. Failure
time was defined in this analysis as the time from the first injection of IT dexamethasone to
the time at which a patient elected to receive IT gentamicin. For those who did not fail IT
dexamethasone treatment, censoring time was defined to be the time from the first injection of
IT dexamethasone to the time of data analysis. All censoring times in our study are, therefore,
considered to be administrative (i.e., censoring due to constraints of when the analysis was
performed rather than a patient actually being lost to follow-up) (15). This appears to be a
reasonable assumption because all patients with Ménière’s disease seen at our institution are
followed up in the clinic regularly and told promptly to call if they experience debilitating
vertigo. This assumption would only be compromised if the patient elected to receive treatment
elsewhere and did not inform his or her clinician at our institution or if a patient died before
the time of data analysis.
The survival curve in Figure 1 demonstrates that 91% of all subjects “survived” (i.e., received
satisfactory vertigo control) with IT dexamethasone treatments given as needed. Very long
follow-up data from some subjects yielded a survival curve that remained fairly flat beyond 2
years. For those 97 subjects with follow-up data at or beyond 2 years, the remission rate
(needing no further intratympanic treatments) was 70%. Before the advent of intratympanic
therapies, Silverstein et al. (17) studied a group of patients with Ménière’s disease who had
failed medical therapy and were offered endolymphatic sac surgery or vestibular neurectomy.
Of their 50 patients who declined any surgery, 57% had complete control of vertigo after 2
years, and 70% had complete control after 8.3 years. These findings indicate a high rate of
spontaneous remission of vertigo in Ménière’s disease even in patients who initially were felt
to have medically refractory disease. In the present study, it is tempting to conclude that IT
dexamethasone treatment led to more rapid remission of Ménière’s disease. However, only a
prospective placebo-controlled study designed specifically to compare remission rates between
gentamicin and palcebo treatment would justify this conclusion, but such a study can be very
difficult to perform.
It may be that IT dexamethasone therapy only provides temporary relief of symptoms and
needs to be repeated until spontaneous remission occurs. The need for repeated injections
would seem to be a disadvantage of IT dexamethasone in comparison with IT gentamicin
treatment. The costs of each injection and the burden of experiencing recurrent vertigo at
somewhat unpredictable times must be considered in this comparison. However, our
experience with IT gentamicin demonstrates that multiple gentamicin injections are not unusual
with titration protocol. The number of IT gentamicin injections needed to produce evidence of
unilateral hypofunction and to control vertigo was 2.8 ± 1.3, and later recurrent vertigo required
more gentamicin injections in 22% of patients (18). The IT gentamicin titration protocol would
appear to have an advantage over IT dexamethasone treatment in clustering mutiple injections
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at the time of initial treatment and decreasing the probability for needing subsequent injections.
However, IT gentamicin treatment carries the risks of worsening the hearing loss in the treated
ear and of causing disequilibrium (1,2) because a reduction in vestibular function is likely the
mechanism by which gentamicin achieves vertigo control (19,20).
Our approach to patients with medically refractory unilateral Ménière’s disease with IT therapy
has evolved. We discuss these advantages and disadvantages of IT dexamethasone versus IT
gentamicin. Intratympanic dexamethasone treatment is encouraged if the patient has frequent
vertigo because the apparently temporary effect would likely only benefit the patient who has
a high probability of having vertigo in the few months after the treatment. If a beneficial effect
is felt by the patient, subsequent injections are offered for recurrent symptoms at intervals of
1 to 3 months. However, if unsatisfactory effect is perceived by the patient, we then recommend
proceeding to IT gentamicin treatment. Conversely, IT gentamicin is encouraged immediately
if the patient has rare but severe attacks.
The growing popularity of IT therapy necessitates a reevaluation of the criteria for evaluating
effectiveness of treatments for Ménière’s disease. The 1995 AAO-HNS criteria for evaluating
treatment outcomes in Ménière’s disease were designed to assess one-time, primarily surgical,
treatments by comparing the average monthly number of attacks of vertigo in the 6 months
before treatment with the same number 18 to 24 months after treatment (13). Repeated office
treatments were not envisioned in the creation of these criteria. However, when the regimen
of as-needed, repeated IT dexamethasone injections is considered as a whole, it compares
favorably with surgical options by the AAO-HNS outcomes criteria because 87 (91%) of
subjects with 2 years or more of follow-up found satisfactory vertigo relief with variable
numbers of IT dexamethasone injectons (Table 1).
However, we suggest that the Kaplan-Meier approach has 2 advantages over these historic
criteria. First, Kaplan-Meier methods allow more efficient use of all available data. Rather than
only looking at subjects who have had a minimum of 2 years of follow-up, the Kaplan-Meier
approach uses all of the available data to model the survival function over time (i.e., the
percentage of patients over time with adequate vertigo control during treatment). Using this
approach, we can therefore observe how vertigo control with a repeated treatment like IT
dexamethasone varies over time rather than simply looking at vertigo control at only a cross-
sectional time point. Second, the Kaplan-Meier approach can use a patient-centered and
clinically relevant outcome measure (“failure” defined as a patient’s choice to receive a
different therapy). This measure is discrete and not subject to recall bias or poor record keeping
of vertigo spells on the part of subjects. Moreover, using the number of vertigo attacks as the
primary outcome measure for treatment success can be problematic. For example, although
class B control may be acceptable to some patients who previously had very frequent or severe
attacks, it may still be very debilitating for other patients. Here, we have instead used a patient-
centered outcome measure defined as when a subject chose to receive ablative IT gentamicin
because his or her vertigo attacks were sufficiently debilitating to his or her lifestyle so that he
or she was willing to accept the risks of ablative therapy. This approach is also consistent with
the current emphasis on patient-centered outcomes and clinical decision making (21).
Hearing outcomes were not quantitatively addressed in this study, but we did not observe
significant hearing changes in the majority of our subjects after IT dexamethasone treatment.
Arriaga and Goldman (22) found that only 33% had hearing improvement, and 20% had hearing
deterioration after IT dexamethasone with hyaluronan. However, Hillman et al. (23) reported
a 40% hearing improvement after IT dexamethasone. Garduno-Anaya et al. (12) also reported
a subjective improvement in tinnitus (48%), hearing loss (35%), and aural fullness (48%) in
the dexamethasone group compared with the control group. The risk of tympanic membrane
perforation appears to be very low in our study (1 instance, 0.8%) and probably related to the
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large number of injections given in that case. This finding suggests that patients requiring very
frequent IT steroid injections should consider switching therapy to IT gentamicin to limit the
total number of injections. The present data will hopefully motivate a well-designed
prospective trial of IT steroids for Ménière’s disease in which both hearing and equilibrium
outcomes would be assessed.
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FIG. 1.
Kaplan-Meier Survival curve showing the percentage of subjects remaining on IT
dexamethasone for vertigo control over time after initial injection. Black line indicates
observed survival; gray lines, 95% confidence interval.
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